Galderma Group AG (SWX:GALD)
160.55
-0.25 (-0.16%)
Oct 2, 2026, 5:30 PM CET
Galderma Group AG Revenue
Galderma Group AG had revenue of $3.15B USD in the half year ending June 30, 2026, with 42.06% growth. This brings the company's revenue in the last twelve months to $5.92B, up 26.29% year-over-year. In the year 2025, Galderma Group AG had annual revenue of $5.24B with 18.04% growth.
Revenue (ttm)
$5.92B
Revenue Growth
+26.29%
P/S Ratio
7.82
Revenue / Employee
$771.63K
Employees
7,676
Market Cap
37.44B CHF
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.24B | 801.00M | 18.04% |
| Dec 31, 2024 | 4.44B | 323.00M | 7.85% |
| Dec 31, 2023 | 4.12B | 293.10M | 7.66% |
| Dec 31, 2022 | 3.82B | 378.90M | 11.00% |
| Dec 31, 2021 | 3.45B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 62.96B |
| Novartis AG | 45.81B |
| Sandoz Group AG | 9.43B |
| Alcon | 8.78B |
| Lonza Group AG | 6.87B |
| Galenica AG | 4.29B |
| Sonova Holding AG | 3.61B |
| Straumann Holding AG | 2.64B |
Galderma Group AG News
- 2 days ago - EADV 2026: Galderma's New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis - Business Wire
- 9 days ago - EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences - Business Wire
- 11 days ago - Galderma Begins Trading in the Swiss Market Index, Joining Switzerland’s Leading Blue Chip Companies - Financial Post
- 14 days ago - Galderma mindful of focus while eyeing product range expansion, CEO tells FuW - Reuters
- 16 days ago - Galderma Reports Positive Topline Results For Restylane Volyme In Temple Hollowing Study - Nasdaq
- 16 days ago - Galderma's Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing - Business Wire
- 27 days ago - Plastic surgery is booming with boomers. Here's how to cash in on the antiaging craze. - Market Watch
- 7 weeks ago - Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping - Business Wire